Vitrafy Life Sciences has launched a non-underwritten Share Purchase Plan to raise approximately A$2 million, offering existing Australian and New Zealand shareholders the chance to buy shares at A$2.60 each, matching the recent institutional placement price.
- Non-underwritten SPP targeting A$2 million
- Offer price set at A$2.60 per share
- Eligible shareholders may subscribe up to A$30,000
- Funds to support Guardion device manufacturing and US expansion
- SPP closes on 3 July 2026 with shares trading from 10 July
Share Purchase Plan Opens After A$30 Million Placement
Vitrafy Life Sciences Limited (ASX:VFY) has kicked off a non-underwritten Share Purchase Plan (SPP) aiming to raise about A$2 million. The offer is open to shareholders on the register as of 11 June 2026 with addresses in Australia or New Zealand. Eligible investors can subscribe for up to A$30,000 worth of new shares at A$2.60 each, the same price as the institutional placement completed just days earlier that raised a hefty A$30 million.
The SPP closes on 3 July 2026, with new shares expected to be issued on 9 July and commence trading on 10 July. Vitrafy reserves the right to scale back applications or close the plan early if demand exceeds the target.
Use of Proceeds Focused on Manufacturing and US Growth
Proceeds from the SPP, combined with the recent placement, will primarily fund manufacturing of Vitrafy’s Guardion cryopreservation devices to meet anticipated demand. Additional capital will accelerate US operations, sales, marketing efforts, and working capital needs. This aligns with the company’s ongoing push to scale its presence in the lucrative US market, following a successful institutional raise priced at a 31.6% discount to the recent closing price.
Participation Details and Eligibility
Participation in the SPP is voluntary and open only to shareholders with registered addresses in Australia or New Zealand, excluding those in the United States or acting on behalf of US persons. Shareholders can apply for parcels ranging from A$2,500 to A$30,000, with no brokerage or transaction fees. The offer is non-transferable and shares issued will rank equally with existing shares.
Applications must be submitted via BPAY or EFT by the closing date. Custodians and nominees can participate on behalf of eligible beneficiaries but must comply with strict US exclusion rules.
Market Risks and Scale Back Provisions
Vitrafy cautions shareholders that the market price of shares may fluctuate between the offer and issue dates, meaning the SPP price may be higher or lower than the market price at allocation. Applications are unconditional and cannot be withdrawn once submitted. If demand exceeds the A$2 million cap, Vitrafy may scale back applications at its discretion, refunding any excess without interest.
The SPP is not underwritten, so the final amount raised depends on shareholder participation. Any shortfall may be placed with institutional or professional investors.
Next Steps and What to Watch
Following the recent A$30 Million to Scale US Operations placement, this SPP offers retail shareholders a chance to join the capital raising at the same price, supporting Vitrafy’s growth ambitions. Investors will be watching the uptake of the SPP closely as an indicator of retail confidence and to gauge the impact on the company’s capital structure. The success of the manufacturing scale-up and US market penetration funded by these raises will be critical to watch in coming quarters.
Bottom Line?
Vitrafy’s SPP offers a straightforward opportunity for retail shareholders to back the company’s US growth and manufacturing scale-up, but final proceeds hinge on participation and potential scale backs.
Questions in the middle?
- Will the SPP reach its A$2 million target or face scale back?
- How effectively will Vitrafy deploy funds to meet Guardion demand and US expansion?
- Could market price fluctuations between offer and issue dates affect shareholder returns?